nach oben

Erschienen in:

30.12.2023

Acromegaly increases depressive symptoms and reduces quality of life of cohabitants

verfasst von: Serhat Uysal, Cem Sulu, Zehra Kara, Ilker Ihtiyaroglu, Irem Ozkal, Serdar Sahin, Sabriye Sibel Taze, Mehmet Murat Kirpinar, Senol Turan, Pinar Kadioglu

Erschienen in: Pituitary | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess how living with patients with acromegaly affects people’s psychology and quality of life (QoL).

Methods

Acromegaly patients and their cohabitants included in this study. Patients were administered Acromegaly Quality of Life Questionnaire (AcroQoL), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI). Cohabitants were administered quality of life questionnaire (SF-36), BAI, BDI, and Zarit Caregiver Burden Interview (ZBI).

Results

This study included 84 patients with acromegaly and 84 cohabitants. Sixty-nine patients (n = 84, 82.1%) had an acromegalic appearance. Cohabitants who were affected by the acromegalic appearance had higher BAI, BDI, and ZBI scores than those who were not affected (p < 0.001 for all). Cohabitants who were affected by the acromegalic appearance had a significantly lower SF-36 score (p = 0.015). The BAI (r=-0.535, p < 0.001), BDI (r=-0.592, p < 0.001), and ZBI (r=-0.465, p < 0.001) scores of the cohabitants showed a negative correlation with AcroQoL. SF-36 scores showed correlation with AcroQoL (r = 0.387, p < 0.001).

Conclusion

The chronic process of acromegaly and the external appearance of patients with this disease can negatively affect both the patients and the people living with them. Physicians being aware of this effect and taking counteractive measures may contribute positively to the course of acromegaly.

Melmed S (2020) Pituitary-Tumor Endocrinopathies. N Engl J Med 382:937–950. https://doi.org/10.1056/NEJMra1810772CrossRefPubMed

Sibeoni J, Manolios E, Verneuil L et al (2019) Patients’ perspectives on acromegaly diagnostic delay: a qualitative study. Eur J Endocrinol 180:339–352. https://doi.org/10.1530/EJE-18-0925CrossRefPubMed

Berg C, Petersenn S, Lahner H et al (2010) Cardiovascular Risk factors in patients with uncontrolled and long-term acromegaly: comparison with Matched Data from the General Population and the Effect of Disease Control. J Clin Endocrinol Metab 95:3648–3656. https://doi.org/10.1210/jc.2009-2570CrossRefPubMed

Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877–884. https://doi.org/10.1530/EJE-10-1050CrossRefPubMed

Trotman-Dickenson B, Weetman AP, Hughes JM (1991) Upper airflow obstruction and pulmonary function in acromegaly: relationship to Disease activity. Q J Med 79:527–538PubMed

Wassenaar MJE, Biermasz NR, van Duinen N et al (2009) High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case–control study. Eur J Endocrinol 160:357–365. https://doi.org/10.1530/EJE-08-0845CrossRefPubMed

Melmed S, Bronstein MD, Chanson P et al (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552–561. https://doi.org/10.1038/s41574-018-0058-5CrossRefPubMedPubMedCentral

Ben-Shlomo A, Sheppard MC, Stephens JM et al (2011) Clinical, quality of life, and economic value of acromegaly Disease control. Pituitary 14:284–294. https://doi.org/10.1007/s11102-011-0310-7CrossRefPubMedPubMedCentral

Christofides EA (2016) Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence Volume 10:1217–1225. https://doi.org/10.2147/PPA.S102302CrossRef

10.

Andela CD, Scharloo M, Pereira AM et al (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18:752–776. https://doi.org/10.1007/s11102-015-0636-7CrossRefPubMed

11.

Kimball A, Dichtel LE, Yuen KCJ et al (2022) Quality of life after long-term biochemical control of acromegaly. Pituitary 25:531–539. https://doi.org/10.1007/s11102-022-01224-0CrossRefPubMedPubMedCentral

12.

Fourneaux R, Vermalle M, Albarel F et al (2021) Acromegaly in remission: a view from the partner. Eur J Endocrinol 185:K19–K23. https://doi.org/10.1530/EJE-21-0537CrossRefPubMed

13.

Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189–3202. https://doi.org/10.1172/JCI39375CrossRefPubMedPubMedCentral

14.

Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700CrossRefPubMed

15.

Webb SM, Badia X, Surinach NL (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269–277. https://doi.org/10.1530/eje.1.02214CrossRefPubMed

16.

Webb SM, Colao A, Caron P et al (2006) A European prospective real-life observational study of quality of life in patients with acromegaly. Endocr Abstr 11:OC20

17.

McHorney CA, Ware J Jr, Raczek AE (1993) The MOS 36-Item short-Form Health Survey (SF-36). Med Care 31:247–263. https://doi.org/10.1097/00005650-199303000-00006CrossRefPubMed

18.

Koçyiğit H, Aydemir Ö, Ölmez N, Memiş A (1999) Kısa form-36 (KF36)’nın Türkçe versiyonunun güvenirliliği ve geçerliliği. İlaç ve Tedavi Derg 12:102–106

19.

Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893–897. https://doi.org/10.1037/0022-006X.56.6.893CrossRefPubMed

20.

Yochim BP, Mueller AE, June A, Segal DL (2010) Psychometric properties of the geriatric anxiety scale: comparison to the Beck anxiety inventory and geriatric anxiety inventory. Clin Gerontol 34:21–33. https://doi.org/10.1080/07317115.2011.524600CrossRef

21.

Ulusoy M, Şahin N, Erkmen H (1998) Turkish version of the Beck anxiety inventory: Psychometric Properties. J Cogn Psychother 12:163–171

22.

Beck A, Ward C, Mendelson M et al (1961) An inventory for Measuring Depression. Arch Gen Psychiatry 4:561–571. https://doi.org/10.1001/archpsyc.1961.01710120031004CrossRefPubMed

23.

Kendall PC, Hollon SD, Beck AT et al (1987) Issues and recommendations regarding use of the Beck Depression Inventory. Cognit Ther Res 11:289–299. https://doi.org/10.1007/BF01186280CrossRef

24.

Hisli N (1989) Beck Depresyon Envanterinin üniversite öğrencileri için geçerliği, güvenirliği. Psikol Derg 7:3–13

25.

Zarit SH, Reever KE, Bach-Peterson J (1980) Relatives of the impaired Elderly: correlates of feelings of Burden. Gerontologist 20:649–655. https://doi.org/10.1093/geront/20.6.649CrossRefPubMed

26.

Bédard M, Molloy DW, Squire L et al (2001) The Zarit Burden interview: a new short version and screening version. Gerontologist 41:652–657. https://doi.org/10.1093/geront/41.5.652CrossRefPubMed

27.

İnci F, Erdem M (2008) Bakım Verme Yükü Ölçeği’nin Türkçe’ye Uyarlanması Geçerlilik Ve Güvenilirliği. Atatürk Üniversitesi Hemşirelik Yüksekokulu Derg 11:85–95

28.

Baron RM, Kenny DA (1986) The moderator–mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51:1173–1182. https://doi.org/10.1037/0022-3514.51.6.1173CrossRefPubMed

29.

Sobel ME (1982) Asymptotic confidence intervals for Indirect effects in Structural equation models. Sociol Methodol 13:290. https://doi.org/10.2307/270723CrossRef

30.

Hayes AF (2009) Beyond Baron and Kenny: Statistical Mediation Analysis in the New Millennium. Commun Monogr 76:408–420. https://doi.org/10.1080/03637750903310360CrossRef

31.

Preacher KJ, Hayes AF (2004) SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instruments Comput 36:717–731. https://doi.org/10.3758/BF03206553CrossRef

32.

Preacher KJ, Hayes AF (2008) Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 40:879–891. https://doi.org/10.3758/BRM.40.3.879CrossRefPubMed

33.

Rowles SV, Prieto L, Badia X et al (2005) Quality of life (QOL) in patients with acromegaly is severely impaired: Use of a Novel measure of QOL: Acromegaly Quality of Life Questionnaire. J Clin Endocrinol Metab 90:3337–3341. https://doi.org/10.1210/jc.2004-1565CrossRefPubMed

34.

Ballesteros-Herrera D, Briseño‐Hernández P, Pérez‐Esparza R, Portocarrero‐Ortiz LA (2021) Differences in quality of life between genders in acromegaly. Endocrinol Diabetes Metab 4. https://doi.org/10.1002/edm2.229

35.

Andela CD, Tiemensma J, Kaptein AA et al (2019) The partner’s perspective of the impact of pituitary Disease: looking beyond the patient. J Health Psychol 24:1687–1697. https://doi.org/10.1177/1359105317695427CrossRefPubMed

36.

Dunning T, Alford F (2009) Pituitary Disease - perspectives of patients and partners. J Nurs Healthc Chronic Illn 1:139–146. https://doi.org/10.1111/j.1752-9824.2009.01014.xCrossRef

37.

Tseng F-Y, Chen S-T, Chen J-F et al (2019) Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan Acromegaly Registry. J Formos Med Assoc 118:1488–1493. https://doi.org/10.1016/j.jfma.2019.05.007CrossRefPubMed

38.

Postma MR, Netea-Maier RT, van den Berg G et al (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166:585–592. https://doi.org/10.1530/EJE-11-0853CrossRefPubMed

39.

Yoshida K, Fukuoka H, Matsumoto R et al (2015) The quality of life in acromegalic patients with biochemical remission by Surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy. Using the Newly Developed Japanese Version of the AcroQoL Pituitary 18:876–883. https://doi.org/10.1007/s11102-015-0665-2CrossRefPubMed

40.

Kepicoglu H, Hatipoglu E, Bulut I et al (2014) Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary 17:557–563. https://doi.org/10.1007/s11102-013-0544-7CrossRefPubMed

41.

Biermasz NR, van Thiel SW, Pereira AM et al (2004) Decreased quality of life in patients with Acromegaly despite Long-Term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369–5376. https://doi.org/10.1210/jc.2004-0669CrossRefPubMed

42.

Kyriakakis N, Lynch J, Gilbey SG et al (2017) Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable Disease: results from a 5-years prospective study. Clin Endocrinol (Oxf) 86:806–815. https://doi.org/10.1111/cen.13331CrossRefPubMed

Titel: Acromegaly increases depressive symptoms and reduces quality of life of cohabitants
verfasst von: Serhat Uysal
Cem Sulu
Zehra Kara
Ilker Ihtiyaroglu
Irem Ozkal
Serdar Sahin
Sabriye Sibel Taze
Mehmet Murat Kirpinar
Senol Turan
Pinar Kadioglu
Publikationsdatum: 30.12.2023
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2024
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-023-01376-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Prediction of adrenal insufficiency after pituitary surgery: a retrospective study using beckman access cortisol assay

Correction: Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study

Different patient versus provider perspectives on living with Cushing’s disease

Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas